



Supplementary Table 1. Patient Demographics by Clinical Response Subgroup.

Characteristic	Responders / Partial-Responders (<i>n</i> = 10)		Non-Responders (<i>n</i> = 6)	
	Pre	Post	Pre	Post
Age, y				
Mean (SD)		35.8 (9.8)		30.2 (8.6)
Range		23-53		18-40
Treatment group		4 CBT / 6 SSRI		4 CBT / 2 SSRI
Early-onset OCD (≤ 10 y), No.		6		4
Predominant compulsion, No.				
Washing		6		2
Checking		4		4
Lifetime history of MDE (2° to OCD symptoms), No.		4		1
Past substance abuse, No.		0		0
	Pre	Post	Pre	Post
Y-BOCS score, mean (SD)	22.5 (3.3)	10.5 (4.2)	24.7 (6.9)	23.3 (4.6)
BDI score, mean (SD)	12.5 (9.8)	6.7 (8.0)	11.0 (6.9)	8.2 (7.9)
Plasma free tryptophan, mean (SD), nmol/L ¹	10.1 (2.2)	10.0 (1.7)	10.1 (2.1)	7.6 (0.8)
Global K*, mean (SD), mL/g/min ¹	5.2 (1.6)	6.5 (1.8)	5.8 (0.4)	5.4 (1.5)
Intravenously injected, mean (SD), mCi ¹	9.5 (1.0)	9.7 (0.5)	9.7 (1.0)	9.6 (0.6)

Abbreviations: OCD, obsessive-compulsive disorder; CBT, cognitive behavioral therapy; SSRI, selective serotonin re-uptake inhibitor; MDE, major depressive episode; Y-BOCS, Yale-Brown Obsessive Compulsive Scale; BDI, Beck Depression Inventory; No., number. Responders/partial-responders demonstrated a > 25% decrease in Y-BOCS score. ¹ Data not included for 1 patient treated with CBT.



Supplementary Figure 1. Mean absolute K* values of **(a)** responders/partial responders ($n = 9$) and **(b)** non-responders ($n = 6$) at 0 weeks (Pre) and 12 weeks (Post) of either CBT or SSRI

treatment in each region of interest. The uncorrected p-values from paired t-tests comparing pre- and post-treatment K^* values are indicated for each ROI. Abbreviations: L, Left; R, Right; Inf Temp, Inferior Temporal; PFC, Prefrontal Cortex; NAcc, Nucleus Accumbens.